ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

Experts Concerned As Phase I Studies Reach Deeper Into Community Practice (Second story in a two-part series.)

April 2, 2010

Kirsten Goldberg Leaves The Cancer Letter For ASCO

January 7, 2011

Michael Link Elected ASCO President.

January 15, 2010

FEBT, For Pain Control, Shows Positive Results In Phase III

May 26, 2006

White House Picks Harold Varmus For NCI

May 21, 2010

Also NCI prostate SPOREs plan biospecimen bank.

December 10, 2004